Feng He

ORCID: 0000-0003-0276-3303
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Glaucoma and retinal disorders
  • Suicide and Self-Harm Studies
  • Traumatic Brain Injury Research
  • Posttraumatic Stress Disorder Research
  • HIV/AIDS Research and Interventions
  • Autophagy in Disease and Therapy
  • Retinal Imaging and Analysis
  • Resilience and Mental Health
  • Kawasaki Disease and Coronary Complications
  • Genomics, phytochemicals, and oxidative stress
  • Cell death mechanisms and regulation
  • Neuropeptides and Animal Physiology
  • Sleep and related disorders
  • Child and Adolescent Psychosocial and Emotional Development
  • Inflammasome and immune disorders
  • Gut microbiota and health
  • Pulmonary Hypertension Research and Treatments
  • Mitochondrial Function and Pathology
  • Liver Disease Diagnosis and Treatment
  • Sex work and related issues
  • Genetics and Neurodevelopmental Disorders
  • Receptor Mechanisms and Signaling
  • Retinal Diseases and Treatments
  • Glutathione Transferases and Polymorphisms
  • RNA Interference and Gene Delivery

University of California, San Diego
2016-2025

Human Longevity (United States)
2021-2024

Wuhan University
2009-2024

Tianjin University of Traditional Chinese Medicine
2024

Zhongnan Hospital of Wuhan University
2009-2024

Chinese Academy of Sciences
2024

Qingdao Institute of Bioenergy and Bioprocess Technology
2024

Qinghai New Energy (China)
2024

Shanghai University of Traditional Chinese Medicine
2021-2023

Zhejiang University of Technology
2022-2023

To examine whether treatment of obstructive sleep apnea (OSA) with continuous positive airway pressure (CPAP) in patients Alzheimer's disease (AD) results better cognitive function.

10.1111/j.1532-5415.2008.01934.x article EN Journal of the American Geriatrics Society 2008-09-15

Liver disease defect identified The energy sensor adenosine monophosphate–activated protein kinase (AMPK) is implicated in liver damage nonalcoholic steatohepatitis (NASH), a leading cause of liver-associated death humans. Zhao et al. used mouse models NASH and samples from human patients to show that AMPK, the activity which lost NASH, phosphorylates enzyme procaspase-6. In normal cells, this modification limits activation caspase-6 consequent caspase cascade leads apoptosis. AMPK may thus...

10.1126/science.aay0542 article EN Science 2020-02-07

ABSTRACT Background There are no FDA‐approved therapies for alcohol‐associated liver disease (ALD). Preclinical studies indicate that blocking IL‐23/IL‐17 signalling may reverse injury. Guselkumab, an IL‐23‐specific antibody approved psoriasis, be beneficial ALD. Aims We aimed to assess the safety and tolerability of guselkumab in patients with Methods This phase‐1 dose‐escalation study included ≥ 2 DSM‐5 criteria alcohol use disorder, significant steatosis (MRI‐PDFF 8%) MRE < 3.63 kPa...

10.1111/apt.70026 article EN Alimentary Pharmacology & Therapeutics 2025-02-14

Abstract Objective : The concept of symptom clusters is relatively new in cancer patients' management. This study, which spanned four cycles chemotherapy, combined three commonly seen pre‐treatment symptoms patients (i.e. sleep disturbances, fatigue and depression) into one cluster, to explore the associations between cluster categories longitudinal profiles these same during chemotherapy. Methods was a prospective study. Seventy‐six women with newly diagnosed stage I–III breast cancer,...

10.1002/pon.1412 article EN Psycho-Oncology 2008-08-01

REPORT insomnia symptoms. 1,2 There is also evidence suggesting that breast cancer patients constitute the subgroup of most at risk for experiencing sleep difficulties. 3,4 In addition to resulting in restless (i.e., increased activity during night), and its treatment may reduce daytime activity.Although data are rather sparse, there some suggest have disturbed circadian rhythms.6][7][8][9] But few examined variables before patients.Some on rhythms be altered even prior initiation...

10.1093/sleep/32.9.1155 article EN SLEEP 2009-09-01

<h3>Objective</h3>To estimate the incidence rate and predictors of seizures in patients with mild to moderate Alzheimer disease (AD).<h3>Design</h3>Cohort study AD clinical trials. Risk factors for potential were evaluated by stratified descriptive statistics univariable multivariable Cox proportional hazards regressions.<h3>Setting</h3>Pooled patient-level data from 10 Disease Cooperative Study trials 1995 2010.<h3>Patients</h3>Three thousand seventy-eight subjects randomized treatment or...

10.1001/archneurol.2011.830 article EN Archives of Neurology 2012-03-01

Abstract In 2015, ~800,000 people died by suicide worldwide. For every death there are as many 25 attempts, which can result in serious injury even when not fatal. Despite this large impact on morbidity and mortality, the genetic influences attempt poorly understood. We performed a genome-wide association study (GWAS) of severity attempts to investigate influences. A discovery GWAS was Yale-Penn sample cohorts European Americans (EAs, n = 2,439) African (AAs, 3,881). found one significant...

10.1038/s41398-018-0340-2 article EN cc-by Translational Psychiatry 2019-01-17

Abstract Objective No drug is yet approved to treat the core symptoms of autism spectrum disorder ( ASD ). Low‐dose suramin was effective in maternal immune activation and Fragile X mouse models . The Suramin Autism Treatment‐1 SAT ‐1) trial a double‐blind, placebo‐controlled, translational pilot study examine safety activity low‐dose children with Methods Ten male subjects , ages 5–14 years, were matched by age, IQ severity into five pairs, then randomized receive single, intravenous...

10.1002/acn3.424 article EN cc-by-nc-nd Annals of Clinical and Translational Neurology 2017-05-26

Although intravenous immunoglobulin (IVIG) is effective therapy for Kawasaki disease, 10-20% of patients have recrudescent fever as a sign persistent inflammation and require additional treatment. We aimed to compare infliximab with second infusion IVIG treatment resistant disease.In this multicentre comparative effectiveness trial, (aged 4 weeks 17 years) disease at least 36 h after completion their first were recruited from 30 hospitals across the USA. Patients randomly assigned (1:1) (2...

10.1016/s2352-4642(21)00270-4 article EN cc-by-nc-nd The Lancet Child & Adolescent Health 2021-10-27
Coming Soon ...